Policy & Regulation
Kalytera Focuses Resources on GVHD and Pain Programs, Terminates Pre-Clinical Programs in Bone Disease
17 April 2018 - - Novato, California- and Tel Aviv, Israel-based cannabinoid therapeutics specialist Kalytera Therapeutics, Inc. (TSX Ventrure: KALY) (OTCQB: KALTF) has terminated its pre-clinical development programs in the treatment of bone disease, the company said.
The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in its product development pipeline.
The terminated programs were evaluating three synthetic endocannabinoid compounds, KAL436, KAL439 and KAL671, in bone fracture healing, and osteogenesis imperfecta and osteoporosis.
In connection with the termination of these programs, Kalytera has terminated its License Agreement with Yissum Research Development company of the Hebrew University of Jerusalem, Ltd., under which Kalytera had licensed rights to KAL436, KAL439 and KAL671.
Kalytera seeks to establish a position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease and the treatment of acute and chronic pain.


Related Headlines